Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
Re: New publication: RVX-297- a novel BD2 selective inhibitor of BET bromodomains.
The authors are primarily affiliated with Zenith with some collaborating authors also from Xtal BioStructures. However, the research started at Resverlogix prior to the Resverlogix/Zenith split......so I'm not sure if Resverlogix or Zenith will highight this manuscript.
